Mulher com eritrodermia, mucosite e pancitopenia
DOI:
https://doi.org/10.12957/bjhbs.2020.53535Resumo
Paciente de 31 anos, portadora de psoríase em tratamento
irregular com metotrexato, ácido fólico e ciclosporina apresentando
quadro de eritrodermia associado a descamação
da epiderme, mucosite e pancitopenia foi admitida para
investigação.
Descritores: Eritrodermia; Mucosite; Pancitopenia; Metotrexato;
Farmacodermia.
Downloads
Referências
Pal S, Haroon TS. Erythroderma: a clinico-etiologic study of 90
cases. Int J Dermatol. 1998;37:104.
Klein A, Landthaler M, Karrer S. Pityriasis rubra pilaris: a review
of diagnosis and treatment. Am J Clin Dermatol. 2010;11:157.
Aringer M, Costenbader K, Daikh D, et al. 2019 European
League Against Rheumatism/American College of Rheumatology
classification criteria for systemic lupus erythematosus. Ann
Rheum Dis. 2019;78:1151.
Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the
staging and classification of mycosis fungoides and Sezary
syndrome: a proposal of the International Society for Cutaneous
Lymphomas (ISCL) and the cutaneous lymphoma task
force of the European Organization of Research and Treatment
of Cancer (EORTC). Blood. 2007; 110:1713.
Akhyani M, Ghodsi ZS, Toosi S, et al. Erythroderma: a clinical
study of 97 cases. BMC Dermatol. 2005;5:5
Martins GA, Arruda L. Tratamento sistêmico da psoríase - Parte
I: metotrexato e acitretina. An Bras Dermatol. 2004;79(3):263-278.
Izraeli S, Vora A, Zwaan CM, et al. How I treat ALL in
Down’s syndrome: pathobiology and management. Blood.
;123:35.
Ataíde DST, Esmanhoto LDK, Helmer KA, et al. Ulceração das
placas psoriáticas - efeito cutâneo adverso do metotrexato em
altas doses no tratamento da psoríase: relato de três casos. An
Bras Dermatol. 2003;78:749-53.
Mockenhaupt M, Dunant A, Paulmann M, et al. Drug Causality
in Stevens‐Johnson Syndrome / Toxic Epidermal Necrolysis in
Europe: Analysis of 10 Years RegiSCAR‐Study. Pharmacoepidemiol
Drug Saf. 2016;25(Supp 3):3.
Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson
syndrome and toxic epidermal necrolysis: assessment of medication
risks with emphasis on recently marketed drugs. The
EuroSCAR-study. J Invest Dermatol. 2008;128:35.